Cystatin-C and inflammatory markers in the ambulatory elderly
|
|
- Grace Bradley
- 6 years ago
- Views:
Transcription
1 The American Journal of Medicine (2005) 118, 1416.e e31 CLINICAL RESEARCH STUDY Cystatin-C and inflammatory markers in the ambulatory elderly Michael G. Shlipak, MD, MPH, a Ronit Katz, PhD, b Mary Cushman, MD, c Mark J. Sarnak, MD, MS, d Catherine Stehman-Breen, MD, MS, e Bruce M. Psaty, MD, MPH, f David Siscovick, MD, MPH, f Russell P. Tracy, PhD, c Anne Newman, MD, MPH, g Linda Fried, MD, MPH h a General Internal Medicine Section, San Francisco Veterans Affairs Medical Center and Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, Calif; b Collaborative Health Studies Coordinating Center, Seattle Wash; c Departments of Medicine and Pathology, University of Vermont, Burlington, Vt; d Division of Nephrology, Department of Medicine, Tufts-New England Medical Center, Boston, Mass; e Amgen Inc., Thousand Oaks, Calif; f Departments of Medicine and Epidemiology, University of Washington, Seattle, Wash; g Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, and Division of Geriatric Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa; and h Renal Section, Medical Service, VA Pittsburgh Healthcare System, Pittsburgh, Pa. KEYWORDS: Kidney disease; Cystatin-C; Inflammation; C-reactive protein; Fibrinogen; Creatinine ABSTRACT PURPOSE: Inflammatory factors are elevated in persons with severe renal dysfunction, but their association across all levels of renal function is unclear. We compared cystatin-c, a novel marker of renal function, with creatinine and estimated glomerular filtration rate (egfr) as predictors of C-reactive protein and fibrinogen levels. METHODS: This study is a cross-sectional analysis to evaluate cystatin-c, creatinine, and egfr as predictors of the inflammatory markers C-reactive protein and fibrinogen. Participants included 4637 ambulatory elderly patients from the Cardiovascular Health Study. Multivariate linear regression was used to determine the independent associations of each renal function measurement with the inflammatory marker outcomes. RESULTS: After adjustment for confounding factors, cystatin-c was correlated with both C-reactive protein (coefficient 0.13; 95% confidence interval: , P.0001) and fibrinogen levels (0.15; , P.0001). Associations were larger than those for creatinine and C-reactive protein (0.05; , P.003) or fibrinogen (0.07; , P.0001). Adjusted levels of C-reactive protein increased incrementally across quintiles of cystatin-c, from a median of 2.2 mg/l in quintile 1 to 3.7 mg/l in quintile 5. In contrast, both C-reactive protein and fibrinogen had U-shaped associations with quintiles of creatinine and egfr, because the inflammatory markers were equivalently elevated in quintiles 1 and 5. CONCLUSIONS: The finding of a significant linear association of cystatin-c and inflammation markers suggests that even small reductions in renal function may be associated with adverse pathophysiologic consequences Elsevier Inc. All rights reserved /$ -see front matter 2005 Elsevier Inc. All rights reserved. doi: /j.amjmed
2 1416.e26 The American Journal of Medicine, Vol 118, No 12, December 2005 Chronic kidney disease is an independent predictor of cardiovascular morbidity and mortality, but the mechanisms underlying this association remain unclear. One potential mediator for cardiovascular risk in the setting of chronic kidney disease is the presence of increased inflammation. A prior study from the Cardiovascular Health Study (CHS) reported that levels of inflammatory and procoagulant biomarkers were moderately elevated among elderly participants with creatinine clearance less than 40 ml/min (Cockroft-Gault equation), but there was no difference in levels between those with creatinine clearance 40 to 60 ml/min and those with creatinine clearance greater than 60 ml/ min. 1 An analysis from the National Health and Nutrition Examination Survey III similarly found that participants with an estimated glomerular filtration rate (egfr) less than 60 ml min 1.73 m 2 (Modification of Diet in Renal Disease equation) had elevated levels of C-reactive protein and fibrinogen compared with participants with an egfr 60 to 89 ml min 1.73 m 2 or greater than 90 ml min 1.73 m 2. 2 The results of these studies suggest a threshold effect whereby inflammatory biomarkers may accumulate only in persons with moderate to severe renal dysfunction. An alternative possibility is that creatinine-based estimates of GFR are not capable of distinguishing gradients in renal function within the presumed normal range. 3 Thus, an association of inflammatory markers with moderately impaired levels of renal function may have been missed. Cystatin-C is a novel marker of renal function that has a more linear association with GFR than creatinine or creatininebased estimates of GFR. 4-6 Cystatin-C has been shown to have stronger and more linear associations with heart failure, mortality, and cardiovascular risk compared with creatinine and egfr. 7-9 On the basis of those findings, we hypothesized that levels of inflammatory markers might also be linearly associated with renal function. In this study, we evaluated the associations of cystatin-c, creatinine, and egfr with C-reactive protein and fibrinogen concentrations among participants in CHS, a cohort of ambulatory elderly persons. Materials and methods Design This is a cross-sectional study conducted from the 1992 to 1993 visit of the CHS. The CHS is a community-based, longitudinal study of adults aged 65 years or more at entry with adherence to the Declaration of Helsinki. The objective Reprint requests should be addressed to Michael G. Shlipak, MD, MPH, General Internal Medicine Section, VA Medical Center (111A1), 4150 Clement St., San Francisco, CA Manuscript submitted April 13, 2005, and accepted in revised form July 28, address:shlip@itsa.ucsf.edu of the study was to evaluate risk factors for the development and progression of cardiovascular disease. 10 The original 5201 study participants were recruited between 1989 and 1990 from 4 US communities: Sacramento County, Calif; Forsyth County, NC; Washington County, Md; and Allegheny County, Pa. 11 An additional 687 African Americans were recruited in 1992 and Eligible participants included individuals sampled at random from Medicare eligibility lists in their respective area and their spouses. Of the total 5888 study participants enrolled in CHS, cystatin-c, creatinine, C-reactive protein, and fibrinogen measurements were available and analyzed in 4637 patients. Measurements Renal function was measured by serum cystatin-c and creatinine levels, and by creatinine-based egfr, using the simplified Modification of Diet in Renal Disease equation. 12 All assays were measured on serum drawn in the morning and stored at 70 C. Cystatin-C was measured in 2003 in a BNII nephelometer (Dade Behring Inc., Deerfield, Ill) using a particle-enhanced immunonepholometric assay (N Latex Cystatin-C). 13 Polystyrene particles were coated with monoclonal antibodies to cystatin-c that agglutinate in the presence of antigen (cystatin-c) to cause an increase in the intensity of scattered light in proportion to the amount of cystatin-c in the sample. The assay range is to mg/l, with the reference range for young, healthy individuals reported as 0.53 to 0.95 mg/l. Intra-assay coefficients of variation range from 2.0% to 2.8%, and interassay coefficients of variation range from 2.3% to 3.1%. Serum creatinine levels were measured at the time of the 1992 to 1993 annual visit using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY), a colorimetric method. Inflammatory markers The outcomes of this study were the serum levels of C-reactive protein and fibrinogen, which were measured using samples from the 1992 to 1993 visit. C-reactive protein was measured on plasma using an automated assay on the BNII nephelometer (Dade Behring Inc.) 14 Fibrinogen was measured in a BBL fibrometer (Becton Dickinson, Cockeysville, Md). 15,16 Covariates considered for statistical adjustment included age, sex, race, smoking status (current, former/never), body mass index, alcohol use (drinks/week), history of hypertension, coronary heart disease (prior myocardial infarction, angina, angioplasty, or bypass surgery), heart failure, left ventricular hypertrophy (by electrocardiogram), and stroke; and levels of low-density lipoprotein cholesterol (calculated), high-density lipoprotein cholesterol, and glucose. Analysis We initially performed univariate correlations of each measure of renal function with the inflammatory markers. Sep-
3 Shlipak et al Cystatin-C and inflammation 1416.e27 Table 1 Unadjusted and multivariate adjusted linear correlations of renal function measurements with C-reactive protein and fibrinogen levels Cystatin-C Serum creatinine egfr 95% CI P value 95% CI P value 95% CI P value Log(CRP) Unadjusted (0.166, 0.220) (0.039, 0.097) ( 0.035, 0.021).650 Adjusted* (0.128, 0.188) (0.024, 0.085) ( 0.049, 0.014).278 Adjusted (0.099, 0.155) (0.017, 0.073) ( 0.048, 0.008).191 Fibrinogen Unadjusted (0.168, 0.222) (0.064, 0.120) ( 0.077, 0.021).001 Adjusted* (0.146, 0.210) (0.048, 0.118) ( 0.067, 0.002).037 Adjusted (0.126, 0.181) (0.042, 0.098) ( 0.059, 0.003).045 egfr estimated glomerular filtration rate; CRP C-reactive protein; BMI body mass index; ECG LVH left ventricular hypertrophy by electrocardiography; LDL low-density lipoprotein; HDL high-density lipoprotein. *Adjusted for age, gender, race, and BMI. Adjusted using multivariate linear regression for age, gender, race, BMI, hypertension, smoking status, alcohol intake, ECG LVH, LDL, HDL, glucose, stroke, heart failure, and coronary heart disease. arately, for each measure of renal function, we conducted multivariate linear regressions that adjusted for all of the covariates listed above. In these models, we log-transformed C-reactive protein levels because their distribution was skewed to the right. The results of these models were also used to compare the strength of association of the various correlates of inflammation, including cystatin-c. To compare levels of each inflammatory marker across the distribution of each renal function measurement, we categorized each renal measure into quintiles and determined the median level of C-reactive protein and mean level of fibrinogen within each quintile. The adjusted mean levels were calculated from the linear regression Y adj.mean Y mean b(x ith.mean X mean ), where Y is the interval dependent, Figure 1 Estimated median level of C-reactive protein (CRP) and mean level of fibrinogen by cystatin-c quintile. Cutpoints for quintiles of cystatin-c: 0.90, , , , 1.28 mg/l.
4 1416.e28 The American Journal of Medicine, Vol 118, No 12, December 2005 Figure 2 Estimated median level of C-reactive protein (CRP) and mean level of fibrinogen by creatinine quintile. Cutpoints for quintiles of creatinine: (in men) 0.86, , , , 1.25 mg/dl; (in women) 0.66, , , , 0.95 mg/dl. X is the covariate, i is one of the k groups, and b is the regression coefficient. For each covariate, there is an additional X term in the equation. To obtain the median adjusted levels of C-reactive protein, we calculated the adjusted mean level of log C-reactive protein (using the above method) and then took the anti-log of our estimates. To compare the strength of correlation with each biomarker among the multiple covariates, we used standardized coefficients for linear variables. These are regression coefficients from a multivariate model that are fitted to standardized data; each observation was subtracted from the cohort mean for that measurement (eg, high-density lipoprotein cholesterol) and divided by the cohort standard deviation. Results Serum levels of cystatin-c, creatinine, C-reactive protein, and fibrinogen were measured in 4637 participants at the 1992 to 1993 visit of the CHS. Among these participants, the mean age was 75 years; 58% were women; and the racial distribution was white (82%), African American (17%), and other (1%). In unadjusted analyses, cystatin-c had significant correlations with both log(crp) and fibrinogen levels (Table 1). These associations were somewhat attenuated in multivariate linear regression analyses. Serum creatinine levels were also associated with both log(crp) and fibrinogen levels in unadjusted and adjusted analyses, but the point estimates were much closer to the null than those of cystatin-c. The 95% confidence intervals comparing the associations of cystatin-c and creatinine with each inflammatory marker did not overlap. Estimated GFR was not significantly associated with log(crp) levels, but was weakly associated with fibrinogen. In an analysis of median C-reactive protein and mean fibrinogen levels across quintiles of each renal measure, both C-reactive protein and fibrinogen levels were incrementally higher across quintiles of cystatin-c. The unadjusted median C-reactive protein concentration ranged from 2.0 mg/l in the lowest quintile to 4.0 mg/l in the highest; multivariate adjustment only minimally diminished this association, with adjusted median levels of 2.2 mg/l in the lowest quintile and 3.7 mg/l in the highest quintile (Figure 1). Similarly, the adjusted mean fibrinogen concentration was higher with each quintile of cystatin-c, from 313 mg/dl in the lowest quintile to 356 mg/dl in the highest quintile (Figure 1). In contrast, the association of both creatinine and egfr quintiles with both inflammatory markers was U-shaped with little difference between the
5 Shlipak et al Cystatin-C and inflammation 1416.e29 Figure 3 Estimated median level of C-reactive protein (CRP) and mean level of fibrinogen by estimated glomerular filtration rate (egfr) quintile. Cutpoints for egfr: 82.8, , , , 55.7 ml min 1.73 m 2. low and high quintiles. For creatinine, the lowest adjusted levels of C-reactive protein (2.6 mg/l) were observed in the second and third quintiles and the lowest fibrinogen levels (325 mg/dl) were in the second quintile; the fifth quintile had the highest median C-reactive protein (3.0 mg/l) and mean fibrinogen (341 mg/dl) levels (Figure 2). Among egfr quintiles, C-reactive protein levels were highest in the first and fifth quintiles (3.0 mg/l and 2.9 mg/l, respectively), and equally low in the third and fourth quintiles (2.6 mg/l) (Figure 3). We compared the associations of all the correlates of log(crp) and fibrinogen levels using multivariate linear regression to determine the relative strength of cystatin-c. On the basis of the adjusted, standardized coefficients, cystatin-c was the second strongest correlate of log(crp) after body mass index, and cystatin-c was the strongest correlate of fibrinogen (Table 2). Discussion In this study of ambulatory elderly adults, cystatin-c, a novel measure of renal function, had a significant and linear association with levels of the inflammatory biomarkers C- reactive protein and fibrinogen. Among all predictors evaluated, cystatin-c was the strongest correlate of fibrinogen and the second strongest correlate of C-reactive protein. In contrast, creatinine and creatinine-based egfr had a much weaker and nonlinear association with the inflammation biomarkers. These findings challenge prior studies suggesting that inflammatory factors were only associated with kidney function below some threshold of GFR. 1,2 The association of end-stage renal disease and severe pre-dialysis renal insufficiency with inflammation has been established in several studies Recently, 2 studies found mild-to-moderate renal insufficiency to be associated with elevated levels of inflammatory biomarkers, but only among subjects with an egfr less than 60 ml min 1.73 m 2. 1,2 Because both studies used creatininebased estimates of GFR to determine renal function, they probably could not distinguish renal function impairment among subjects with presumed normal GFR. Because cystatin-c is not a breakdown product of muscle and does not vary with age, sex, and lean muscle mass, we were able to identify a much more graded association of renal function with C-reactive protein and fibrinogen than was possible using creatinine or egfr. Presumably, the association of cystatin-c with these inflammatory biomarkers reflects the underlying association of cystatin-c with kidney function. Several studies have
6 1416.e30 The American Journal of Medicine, Vol 118, No 12, December 2005 Table 2 Log(CRP) Independent predictors of C-reactive protein and fibrinogen levels, ranked by strength of association Fibrinogen Covariate Standardized coefficient* P value Covariate Standardized coefficient* P value BMI (kg/m 2 ) Cystatin-C (mg/l) Cystatin-C (mg/l) LDL (mg/dl) Male sex Non-white race Current smoking Smoking status AAI AAI HDL (mg/dl) HDL (mg/dl) Age BMI (kg/m 2 ) Glucose (mg/dl) Heart failure Heart failure Male sex Coronary heart disease Alcohol use (drinks/wk) Non-white race Coronary heart disease Left ventricular hypertrophy Hypertension Prior stroke Alcohol use (drinks/wk) CRP C-reactive protein; BMI body mass index; AAI ankle arm index; HDL high-density lipoprotein; LDL low-density lipoprotein. *Standardized coefficients are regression coefficients from a multivariate model fitted to standardized data; each observation was subtracted from the cohort mean for that measurement (eg, HDL) and divided by the cohort standard deviation. reported that cystatin-c has a stronger association with measured GFR than serum creatinine 4 or creatinine estimates of GFR. 5,6 Furthermore, in a 4-year longitudinal study in persons with diabetes, but without chronic kidney disease, Perkins and colleagues 21 found that cystatin-c correlated tightly with serial measurements of GFR by iothalamate clearance, whereas the creatinine-based Modification of Diet in Renal Disease was a much weaker reflection of GFR. We have no evidence to suggest that cystatin-c is itself a marker of inflammation, other then being a proxy of kidney function. A recent editorial, 22 however, suggested that cystatin-c s association with cardiovascular outcomes was caused by its role as an inflammatory marker, although those analyses were adjusted for C-reactive protein, fibrinogen, albumin, and factor VIII concentration. 8,9,23 Knight and colleagues 24 have also reported that cystatin-c was influenced by several nonrenal factors, but they compared cystatin-c with creatinine clearance rather than the gold standard of directly measured GFR. Creatinine clearance is known to be an imprecise measure of GFR. 25 This study has limitations that should be considered. Most importantly, it was cross-sectional, so we cannot determine the direction of the association between cystatin-c and inflammation. In addition, we may have missed underlying confounders that would explain the association of cystatin-c with inflammation; conversely, we may have also underestimated the effect of kidney function by adjusting for characteristics, such as hypertension, that may be a consequence of kidney disease. Cystatin-C and creatinine assays were not performed at the same time, although cystatin-c levels seem stable after several years of frozen storage. 26 The substantial differences between the associations of cystatin-c and creatinine with inflammatory markers observed in CHS may be smaller in other populations, such as the non-elderly. In summary, cystatin-c levels are a significant linear correlate of the inflammatory biomarkers C-reactive protein and fibrinogen. These findings suggest that even small reductions in renal function may be associated with adverse physiology. In research settings cystatin-c may offer the opportunity to evaluate the physiologic correlates of renal function across a broad spectrum that would not have been distinguishable with creatinine. Future studies should address whether cystatin-c will have a role in clinical medicine. Acknowledgments Drs. Shlipak, Fried, and Katz are funded by R01 HL Dr. Shlipak is also supported by the American Federation for Aging Research and National Institute on Aging (Paul Beeson Scholars Program) and the Robert Wood Johnson Foundation (Generalist Faculty Scholars Program). Dr. Sarnak is supported by a K23 award from the National Institute of Diabetes and Digestive and Kidney Diseases. The CHS Study is supported by contracts N01-HC to N01-HC-85086, N01-HC-35129, and N01 HC from the National Heart, Lung, and Blood Institute. A full list of participating CHS investigators and institutions can be found at
7 Shlipak et al Cystatin-C and inflammation 1416.e31 References 1. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107(1): Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140(1): Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12): Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2): Hojs R, Bevc S, Antolinc B, et al. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res. 2004;24(2-3): Grubb A, Nyman U, Bjork J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem. 2005;51(8): Jernberg T, Lindahl B, James S, et al. Cystatin C. A novel predictor of outcome in suspected or confirmed non-st-elevation acute coronary syndrome. Circulation. 2004;110; Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20): Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7): Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1: Tell GS, Fried LP, Hermanson B, et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3(4): K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(Suppl 2):S1-S Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59(1): Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43(1): Tracy RP, Arnold AM, Ettinger W, et al. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(7): Cushman M, Cornell ES, Howard PR, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41(2): Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis. 1994;23(6): Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32(1): Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54(2): Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5): Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16(5): Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem. 2005;51(2): Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51(2): Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4): Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6): Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43(6 Pt 1):
PERIPHERAL ARTERIAL DISEASE
ORIGINAL INVESTIGATION Cystatin C and Incident Peripheral Arterial Disease Events in the Elderly Results From the Cardiovascular Health Study Ann M. O Hare, MD, MA; Anne B. Newman, MD, MPH; Ronit Katz,
More informationjournal of medicine The new england Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons abstract
The new england journal of medicine established in 1812 may 19, 2005 vol. 352 no. 20 Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons Michael G. Shlipak, M.D., M.P.H., Mark
More informationThere is a high prevalence of chronic kidney disease
CLINICAL INVESTIGATIONS Kidney Function and Mortality in Octogenarians: Cardiovascular Health Study All Stars Shani Shastri, MD, MPH, MS, a Ronit Katz, DPhil, b Dena E. Rifkin, MD, MS, c Linda F. Fried,
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationInternational Journal of Pharma and Bio Sciences IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS?
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE BIO CHEMISTRY IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS? Corresponding Author R.KUMARESAN Department
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAnnals of Epidemiology
Annals of Epidemiology 23 (2013) 106e111 Contents lists available at SciVerse ScienceDirect Annals of Epidemiology journal homepage: www.annalsofepidemiology.org Hypertension and low HDL cholesterol were
More informationC-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
Kidney International, Vol. 68 (2005), pp. 766 772 C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease VANDANA MENON, TOM GREENE, XUELEI WANG,
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationUric Acid and Incident Kidney Disease in the Community
CLINICAL EPIDEMIOLOGY www.jasn.org Uric Acid and Incident Kidney Disease in the Community Daniel E. Weiner,* Hocine Tighiouart, Essam F. Elsayed,* John L. Griffith, Deeb N. Salem, and Andrew S. Levey*
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationGlomerular filtration rate estimated by cystatin C among different clinical presentations
http://www.kidney-international.org & 2006 International Society of Nephrology Glomerular filtration rate estimated by cystatin C among different clinical presentations AD Rule 1,2, EJ Bergstralh 3, JM
More informationAntiviral Therapy 13:
Antiviral Therapy 13:1091 1095 Short communication Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients Stefan Mauss
More informationMild to moderate reductions in kidney function are
Annals of Internal Medicine Article Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease Vandana Menon, MD, PhD; Michael G. Shlipak, MD, MPH; Xuelei Wang, MS; Josef Coresh, MD, PhD; Tom Greene,
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationIs the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?
Diabetes Care Publish Ahead of Print, published online October 3, 2008 The MCQ equation in DM2 patients Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration
More informationCystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications
Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications Carmen A. Peralta,* Ronit Katz, Mark J. Sarnak, Joachim Ix, Linda F. Fried, Ian De Boer,** Walter Palmas, David Siscovick,
More informationCystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Cystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes IAN H. DE BOER, MD, MS 1 RONIT KATZ, DPHIL 1 JIE J. CAO, MD,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationResearch Article Preinterventional Cystatin C: A Highly Prognostic Marker for All-Cause Mortality after Coronarography
Advances in Nephrology, Article ID 510209, 6 pages http://dx.doi.org/10.1155/2014/510209 Research Article Preinterventional Cystatin C: A Highly Prognostic Marker for All-Cause Mortality after Coronarography
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationClinical Investigations
Clinical Investigations Association of Cystatin C with Ischemia in Patients with Coronary Heart Disease Address for correspondence: Rajat Deo, MD 3400 Spruce Street 9 Founders Cardiology Philadelphia,
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationCystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study
Journal of Cardiac Failure Vol. 12 No. 8 2006 Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study JOACHIM H. IX, MD, 1,2 MICHAEL G. SHLIPAK, MD, MPH,
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction
Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationClinical Usefulness of Serum Cystatin C as a Marker of Renal Function
Original Article Complications Diabetes Metab J 214;38:278-284 http://dx.doi.org/1.493/dmj.214.38.4.278 pissn 2233-79 eissn 2233-87 DIABETES & METABOLISM JOURNAL Clinical Usefulness of Serum Cystatin C
More informationCARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS
CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master
More informationFactors influencing serum cystatin C levels other than renal function and the impact on renal function measurement
Kidney International, Vol. 65 (2004), pp. 1416 1421 Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement ERIC L. KNIGHT, JACOBIEN C. VERHAVE,
More informationCystatin C, albuminuria, and mortality among older adults with diabetes mellitus
Diabetes Care Publish Ahead of Print, published online July 8, 2009 Cystatin C, albuminuria, and mortality Cystatin C, albuminuria, and mortality among older adults with diabetes mellitus Ian H. de Boer,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMetabolic syndrome is a constellation of cardiovascular
and Cognitive Decline in Elderly Latinos: Findings from the Sacramento Area Latino Study of Aging Study Kristine Yaffe, MD, wzk Mary Haan, DrPH, MPH, z Terri Blackwell, MA, # Elena Cherkasova, BA, Rachel
More informationChronic Kidney Disease Prevalence and Rate of Diagnosis
The American Journal of Medicine (2007) 120, 981-986 CLINICAL RESEARCH STUDY Chronic Kidney Disease Prevalence and Rate of Diagnosis Timothy P. Ryan, PhD, a James A. Sloand, MD, b Paul C. Winters, MS,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationC - Reactive Protein, Coronary Heart Disease and Ischemic Stroke in the Elderly: The Cardiovascular Health Study
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2006 C - Reactive Protein, Coronary Heart Disease and Ischemic Stroke in the Elderly: The Cardiovascular Health
More informationKidney Function and Systolic Blood Pressure New Insights From Cystatin C: Data from the Heart and Soul Study
AJH 2006; 19:939 946 Kidney Function and Systolic Blood Pressure New Insights From Cystatin C: Data from the Heart and Soul Study Kidney Carmen A. Peralta, Mary A. Whooley, Joachim H. Ix, and Michael G.
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationFibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals
Journal of the American College of Cardiology Vol. 60, No. 3, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.040
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationCHRONIC KIDNEY DISEASE (CKD)
ORIGINAL CONTRIBUTION ONLINE FIRST Detection of Chronic Kidney Disease With,, and Urine Albumin-to- Ratio and Association With Progression to End-Stage Renal Disease and Mortality Carmen A. Peralta, MD,
More informationThe Association Between Cystatin C and Frailty Status in Older Men
The Association Between Cystatin C and Frailty Status in Older Men A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Allyson Hart IN PARTIAL FULFILLMENT OF THE
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationORIGINAL INVESTIGATION. Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly
Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly The Cardiovascular Health Study ORIGINAL INVESTIGATION Nicholas L. Smith, PhD, MPH; Joshua
More informationFactors other than glomerular filtration rate affect serum cystatin C levels
original article http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 578 Factors other than glomerular filtration rate affect serum cystatin C levels Lesley
More informationImpact of Elevated Cystatin C Level on Cardiovascular Disease Risk in Predominantly High Cardiovascular Risk Populations A Meta-Analysis
Impact of Elevated Cystatin C Level on Cardiovascular Disease Risk in Predominantly High Cardiovascular Risk Populations A Meta-Analysis Meng Lee, MD; Jeffrey L. Saver, MD; Wen-Hung Huang, MD; Jessica
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationImpact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction
ORIGINAL ARTICLE JIACM 2010; 11(4): 277-81 Impact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction Shagun Sachdeva*, NP Singh**, Renuka Saha*** Abstract The presence of coexisting conditions
More information( 1) Framingham Heart
( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health
More informationLongitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes
Article Longitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes Willem J. Kop,* Stephen L. Seliger,* Jeffrey C. Fink,* Ronit Katz,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationHHS Public Access Author manuscript Am J Kidney Dis. Author manuscript; available in PMC 2017 July 05.
HHS Public Access Author manuscript Published in final edited form as: Am J Kidney Dis. 2017 March ; 69(3): 482 484. doi:10.1053/j.ajkd.2016.10.021. Performance of the Chronic Kidney Disease Epidemiology
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationRisk for chronic kidney disease increases with obesity: Health Survey for England 2010
Public Health Nutrition: 18(18), 3349 3354 doi:10.1017/s1368980015000488 Risk for chronic kidney disease increases with obesity: Health Survey for England 2010 Helen L MacLaughlin 1,2, *, Wendy L Hall
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationThe estimation of kidney function with different formulas in overall population
137 G E R I A T R I A 213; 7: 137-141 Akademia Medycyny ARTYKUŁ ORYGINALNY/ORIGINAL PAPER Otrzymano/Submitted: 28.8.213 Zaakceptowano/Accepted: 2.9.213 The estimation of kidney function with different
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationHHS Public Access Author manuscript Obes Res Clin Pract. Author manuscript; available in PMC 2015 April 20.
The association between body composition and cystatin C in South Asians: Results from the MASALA study Arti D. Shah *, Division of Endocrinology and Metabolism, University of California, San Francisco,
More informationThe impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne
University of Groningen The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationRecently, the National Kidney Foundation endorsed a
Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease Andrew D. Rule, MD; Timothy S. Larson, MD; Erik J. Bergstralh, MSc; Jeff M. Slezak,
More informationCystatin C Den svenske erfaringen.
Cystatin C Den svenske erfaringen. Cystatin C some basic facts the new IFCC cystatin C calibrator assay harmonization between different companies cystatin C not just a new marker for renal function! the
More informationThe relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan
Environ Health Prev Med (2011) 16:191 195 DOI 10.1007/s12199-010-0183-9 SHORT COMMUNICATION The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Nobuyuki
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,
More informationAssociation between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study
J Am Soc Nephrol 14: 3233 3238, 2003 Association between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study JOACHIM H. IX,* MICHAEL G. SHLIPAK,*
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationNowadays it is often assumed that impaired renal function
Influence of Age and Measure of egfr on the Association between Renal Function and Cardiovascular Events Marije van der Velde, Stephan J.L. Bakker, Paul E. de Jong, and Ron T. Gansevoort Division of Nephrology,
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationIncidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis
http://www.kidney-international.org & 29 International Society of Nephrology original article Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis
More informationAssociation of Chronic Kidney Disease and Anemia with Physical Capacity: The Heart and Soul Study
J Am Soc Nephrol 15: 2908 2915, 2004 Association of Chronic Kidney Disease and Anemia with Physical Capacity: The Heart and Soul Study MICHELLE C. ODDEN,* MARY A. WHOOLEY,* and MICHAEL G. SHLIPAK* *Section
More informationORIGINAL ARTICLE Estimating the glomerular filtration rate using serum cystatin C levels in patients with spinal cord injuries
(2012) 50, 778 783 & 2012 International Society All rights reserved 1362-4393/12 www.nature.com/sc ORIGINAL ARTICLE Estimating the glomerular filtration rate using serum cystatin C levels in patients with
More informationSupplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
More informationArticle. Chronic Kidney Disease in Octogenarians
Article Chronic Kidney Disease in Octogenarians Shani Shastri,* Hocine Tighiouart,* Ronit Katz, Dena E. Rifkin, Linda F. Fried, Michael G. Shlipak, Anne B. Newman, and Mark J. Sarnak* Summary Background
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationEstimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C Lesley A. Inker, M.D., Christopher H. Schmid, Ph.D., Hocine
More informationCardiovascular and renal outcome in subjects with K/DOQI stage 1 3 chronic kidney disease: the importance of urinary albumin excretion
Nephrol Dial Transplant (2008) 23: 3851 3858 doi: 10.1093/ndt/gfn356 Advance Access publication 18 July 2008 Original Article Cardiovascular and renal outcome in subjects with K/DOQI stage 1 3 chronic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More information